<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！ 投稿请发：442015666@qq.com 推广合作请联系：15057280775/15858667450</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 13 Jun 2021 07:18:01 +0800</pubDate><image><url>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzUxOTgxNzg4NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>300多亿美元大市场，全球多肽药物8大重磅品种</title><link>https://mp.weixin.qq.com/s/fEVChH4H78rir75Ni0oURQ</link><description></description><content:encoded><![CDATA[300多亿美元大市场，全球多肽药物8大重磅品种]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧</title><link>https://mp.weixin.qq.com/s/JDN0aaoXA4KAuAcpRp2jMg</link><description></description><content:encoded><![CDATA[Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>新药研发质量体系建设与管理</title><link>https://mp.weixin.qq.com/s/gdT-5aeYTzBwkrGhfbevbg</link><description></description><content:encoded><![CDATA[新药研发质量体系建设与管理]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>首个国产ADC获批！荣昌生物管线中还有哪些重磅药？</title><link>https://mp.weixin.qq.com/s/MH2LNoRAW12PYh-xF6F6Gw</link><description></description><content:encoded><![CDATA[首个国产ADC获批！荣昌生物管线中还有哪些重磅药？]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>CML靶向药物评价指标，CDE征求《慢性髓性白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见</title><link>https://mp.weixin.qq.com/s/4ReErH8PMLReFO5PJXaZUg</link><description></description><content:encoded><![CDATA[CML靶向药物评价指标，CDE征求《慢性髓性白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见]]></content:encoded><pubDate>Sat, 12 Jun 2021 19:43:18 +0800</pubDate></item><item><title>原料药中亚硝胺杂质的风险评估实操</title><link>https://mp.weixin.qq.com/s/RA9iDoY63zOqShInohnneQ</link><description></description><content:encoded><![CDATA[原料药中亚硝胺杂质的风险评估实操]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧</title><link>https://mp.weixin.qq.com/s/xO_GpPA3pKvKV8L3ibQEBw</link><description></description><content:encoded><![CDATA[Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>2021ASCO重磅登场，亚盛、百济、君实……，国内创新药企谁领风骚？</title><link>https://mp.weixin.qq.com/s/1qwT1cYAqFSbVZOqhNjJ8Q</link><description></description><content:encoded><![CDATA[2021ASCO重磅登场，亚盛、百济、君实……，国内创新药企谁领风骚？]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>已导致3名专家辞任！FDA争议AD新药​Aduhelm！</title><link>https://mp.weixin.qq.com/s/4DiF5eKRpK7H7rtT5zX7Dw</link><description></description><content:encoded><![CDATA[已导致3名专家辞任！FDA争议AD新药​Aduhelm！]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>2021.06.10药品批件信息！21个药品通过一致性评价</title><link>https://mp.weixin.qq.com/s/inrwVyOfNZUx38XvZAqJZQ</link><description></description><content:encoded><![CDATA[2021.06.10药品批件信息！21个药品通过一致性评价]]></content:encoded><pubDate>Fri, 11 Jun 2021 17:03:26 +0800</pubDate></item><item><title>拜耳：在众多制药巨头相继放弃多元化之际逆道而行，是对还是错？</title><link>https://mp.weixin.qq.com/s/g5-IbspcbRcPCVoZfss4FQ</link><description></description><content:encoded><![CDATA[拜耳：在众多制药巨头相继放弃多元化之际逆道而行，是对还是错？]]></content:encoded><pubDate>Fri, 11 Jun 2021 08:19:39 +0800</pubDate></item><item><title>液相故障排除指南(十一)：色谱柱压力</title><link>https://mp.weixin.qq.com/s/nElTx2sfkefMPusJg1D5cA</link><description></description><content:encoded><![CDATA[液相故障排除指南(十一)：色谱柱压力]]></content:encoded><pubDate>Fri, 11 Jun 2021 08:19:39 +0800</pubDate></item><item><title>FDA专家对粒度控制的要求及解释与看法</title><link>https://mp.weixin.qq.com/s/3_onPiIqUsKTbUHoz-zH4A</link><description></description><content:encoded><![CDATA[FDA专家对粒度控制的要求及解释与看法]]></content:encoded><pubDate>Fri, 11 Jun 2021 08:19:39 +0800</pubDate></item><item><title>2021全球基因治疗CRO/CDMO梯队排名</title><link>https://mp.weixin.qq.com/s/eoptueHRw1stez1HlNgh8Q</link><description></description><content:encoded><![CDATA[2021全球基因治疗CRO/CDMO梯队排名]]></content:encoded><pubDate>Wed, 09 Jun 2021 18:01:03 +0800</pubDate></item><item><title>药物固体形态筛选新思路｜实验+预测药物晶型筛选</title><link>https://mp.weixin.qq.com/s/UD4LzNEwePCAXKfl2ODRrQ</link><description></description><content:encoded><![CDATA[药物固体形态筛选新思路｜实验+预测药物晶型筛选]]></content:encoded><pubDate>Wed, 09 Jun 2021 18:01:03 +0800</pubDate></item><item><title>Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧</title><link>https://mp.weixin.qq.com/s/IrsJ_Z4NrkVgvA---FaPqA</link><description></description><content:encoded><![CDATA[Hi，医药人！这个八月跟着药融圈全面玩转CMC-China吧]]></content:encoded><pubDate>Wed, 09 Jun 2021 18:01:03 +0800</pubDate></item><item><title>中国临床试验5月分析：新公示246项试验，BE试验数较上月下降28%，涉及罗氏、诺华、恒瑞、正大天晴等136款新药</title><link>https://mp.weixin.qq.com/s/AoRwBEOTuZ63bsB70Uo7sg</link><description></description><content:encoded><![CDATA[中国临床试验5月分析：新公示246项试验，BE试验数较上月下降28%，涉及罗氏、诺华、恒瑞、正大天晴等136款新药]]></content:encoded><pubDate>Wed, 09 Jun 2021 18:01:03 +0800</pubDate></item><item><title>热门依旧：奥希替尼首家国产申报上市；竞争格局激烈</title><link>https://mp.weixin.qq.com/s/SDHNEkRLMoM3lmaG7j7n3Q</link><description></description><content:encoded><![CDATA[热门依旧：奥希替尼首家国产申报上市；竞争格局激烈]]></content:encoded><pubDate>Wed, 09 Jun 2021 18:01:03 +0800</pubDate></item><item><title>针对难溶性药物溶解度问题“对症下药”</title><link>https://mp.weixin.qq.com/s/W5kKVgVlSnRzL-kqxGEMlQ</link><description></description><content:encoded><![CDATA[针对难溶性药物溶解度问题“对症下药”]]></content:encoded><pubDate>Tue, 08 Jun 2021 22:52:24 +0800</pubDate></item><item><title>产品年度质量回顾（一）</title><link>https://mp.weixin.qq.com/s/-wbSlzsXr-O7LdvgW1qqBg</link><description></description><content:encoded><![CDATA[产品年度质量回顾（一）]]></content:encoded><pubDate>Tue, 08 Jun 2021 22:52:24 +0800</pubDate></item></channel></rss>